Henry Meds GLP-1 review: is it worth it?

What is Henry Meds and how does its GLP-1 program work?

Henry Meds (henrymeds.com) is a telehealth company that prescribes treatments for weight management, hormone therapy, and sexual health. Its weight-loss line is built around GLP-1 receptor agonists. Henry is not a drug manufacturer and not, by itself, a pharmacy — it is the connective layer between you, a state-licensed prescribing clinician, and a contracted compounding pharmacy that fills the order.

The process follows the standard telehealth weight-loss model, with one notable difference in clinical touchpoint:

1. Intake questionnaire. You answer questions about your weight, BMI, medical history, current medications, and goals. GLP-1 therapy for weight is generally appropriate for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia (per FDA labeling for Wegovy and Zepbound).
2. Provider visit. A licensed healthcare provider reviews your submission. Depending on your state, Henry offers either a live two-way video visit (conducted through Doxy, a HIPAA-compliant platform) or an asynchronous independent provider review without video. The live-video option is a meaningfully stronger clinical touchpoint than the asynchronous, questionnaire-only model many competitors default to.
3. Prescription and fulfillment. If the provider determines treatment is appropriate, the prescription is routed to a contracted U.S.-licensed compounding pharmacy, which prepares your medication and ships it to you. Henry reports most patients receive their medication within roughly 8–10 business days.
4. Ongoing care. Dose titration, messaging-based check-ins, and refills are handled through the platform.

Henry's defining commercial feature is its bundled, all-inclusive pricing: a single monthly payment covers the provider visit, the medication, supplies (needles, syringes, alcohol swabs), shipping, and ongoing care, with no separate membership fee. Cold-chain shipments typically arrive with insulated packaging and ice packs, and reviewers consistently note that Henry tends to include anti-nausea medication (ondansetron) proactively — a small but genuinely thoughtful detail given how common early GLP-1 nausea is.

What medications does Henry actually dispense?

Henry offers compounded semaglutide and compounded tirzepatide in both injectable and oral formats. The injectables are the closest analogs to the branded drugs and carry the strongest evidence base. The oral compounded versions are convenient but rest on far weaker ground — there is no FDA-approved oral tirzepatide, and FDA-approved oral semaglutide (Rybelsus) is dosed and absorbed very differently from a compounded troche or drop, so oral-compounded efficacy should not be assumed equivalent to the injectable trial data below.

What are compounded semaglutide and tirzepatide?

Semaglutide is the active ingredient in Ozempic and Wegovy (Novo Nordisk); tirzepatide is the active ingredient in Mounjaro and Zepbound (Eli Lilly). A *compounded* version is a drug mixed by a pharmacy rather than mass-manufactured and approved as a finished product.

This is not a technicality. Compounded drugs are not FDA-approved and are not evaluated by the FDA for safety, effectiveness, or quality (FDA). The agency does not review the formulation, potency, or purity of a compounded GLP-1 before it reaches patients. Consequently, the clinical efficacy data below comes from the *branded* molecules — not from the specific product Henry ships — and equivalence is assumed, not proven.

Compounding pharmacies fall into two categories. 503A pharmacies compound patient-specific prescriptions under state board of pharmacy oversight. 503B outsourcing facilities produce larger batches under tighter, FDA-registered quality requirements. Most telehealth GLP-1 supply has historically run through 503A pharmacies, which operate under lighter manufacturing oversight than either a 503B facility or an FDA-approved manufacturer.

How well do these drugs work?

The molecules themselves are among the most effective anti-obesity medications ever studied — but the evidence comes from the brand-name drugs, not from compounded copies.

Semaglutide (STEP 1 trial, NEJM 2021). In a 68-week randomized trial of 1,961 adults with overweight or obesity (without diabetes), once-weekly semaglutide 2.4 mg produced a mean weight loss of 14.9% of body weight versus 2.4% with placebo (Wilding et al., *NEJM* 2021; PMID 33567185).

Tirzepatide (SURMOUNT-1 trial, NEJM 2022). In a 72-week trial of adults with obesity or overweight (without diabetes), once-weekly tirzepatide produced mean weight loss of 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, versus 3.1% with placebo (Jastreboff et al., *NEJM* 2022; PMID 35658024).

Head-to-head (SURMOUNT-5, NEJM 2025). The first major head-to-head trial randomized adults with obesity (without diabetes) to tirzepatide or semaglutide for 72 weeks. Tirzepatide produced a mean weight loss of 20.2% versus 13.7% for semaglutide (Aronne et al., *NEJM* 2025; PMID 40353578). The likely reason: tirzepatide is a dual GIP/GLP-1 receptor agonist, while semaglutide acts on GLP-1 alone.

The honest limitation: these results belong to FDA-approved Ozempic/Wegovy and Mounjaro/Zepbound. There are no large randomized trials proving that a given compounded product — especially an oral one — delivers identical potency, purity, or results. If a compounded injectable is correctly formulated with the same molecule at the same dose, comparable effects are reasonable to expect, but "reasonable to expect" is not "proven," and the FDA has documented real-world variability in compounded GLP-1 products.

How does the medication work in the body?

GLP-1 receptor agonists mimic an incretin hormone the gut releases after eating. They (1) stimulate glucose-dependent insulin secretion, (2) suppress glucagon, (3) slow gastric emptying so you feel full longer, and (4) act on appetite centers in the hypothalamus to reduce hunger and food "noise." Tirzepatide adds activity at the GIP receptor, a second incretin pathway thought to contribute to its larger average weight-loss effect. The net result is reduced calorie intake driven by genuinely reduced appetite — not willpower.

What does Henry Meds actually cost?

Henry's pricing is bundled — the quoted monthly figure includes the visit, medication, supplies, and shipping — but it is also dose-dependent and partly hidden until intake, which is the single most important thing to understand before signing up.

Publicly reported figures (which shift over time and by promotion) generally fall in these ranges:

• Oral compounded semaglutide: roughly $149–$249/month
• Injectable compounded semaglutide: roughly $297–$397/month, with multi-month bundles (6- or 12-month commitments) lowering the effective monthly rate
• Oral compounded tirzepatide: roughly $199–$349/month
• Injectable compounded tirzepatide: roughly $297–$399/month

Two caveats matter enormously. First, introductory "from $XX" pricing reflects the lowest starting dose. GLP-1 dosing escalates substantially over the first several months, and Henry's cost typically rises at each dose step-up — by roughly $100 per step on injectables, per multiple reviews. The headline starter price is rarely what a patient pays at a maintenance dose. Second, much of the pricing is not visible until you begin the intake quiz or speak with a provider, which makes apples-to-apples comparison shopping harder than it should be. Budget for the maintenance-dose price, not the teaser.

For context, brand-name Wegovy and Zepbound carry list prices of roughly $1,000+/month before insurance — which is precisely why demand for compounded options exploded. But the cash-pay gap has narrowed sharply: as of late 2025, both manufacturers sell self-pay vials directly to patients (Eli Lilly's LillyDirect offers Zepbound vials at roughly $299–$449/month depending on dose; Novo Nordisk's NovoCare offers Wegovy at roughly $199–$399/month, and Wegovy pills around $149–$299), often paired with a telehealth prescription. For some doses these branded cash prices now overlap with — or even undercut — compounded injectable pricing, so a current LillyDirect/NovoCare quote is worth checking before assuming compounded is the cheaper route.

Is Henry Meds legitimate and safe? The regulatory picture you must understand

This is where Henry — and every compounded-GLP-1 telehealth service — requires real scrutiny, because the legal foundation of the entire model has shifted.

The shortage exception has ended. Compounding of "essentially a copy" of an FDA-approved drug is normally prohibited, but it was broadly permitted while the branded drugs were on the FDA shortage list. The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved on February 21, 2025 (FDA). Enforcement discretion for 503A pharmacies compounding semaglutide ended around April 22, 2025, and for 503B outsourcing facilities around May 22, 2025 (FDA). In short: the blanket legal basis for mass-compounding straight copies of these drugs is gone.

What's still legal — and the gray zone. Pharmacies may still compound a product that is *not* essentially a copy — for example, a different dose or a formulation altered for a documented clinical reason (such as an allergy to an inactive ingredient). Many telehealth platforms have pivoted to "personalized" formulations, oral routes, or combination products to stay inside this exception. Whether a given product genuinely qualifies, versus being a copy in disguise, is contested and is exactly what regulators and courts are now examining.

Henry-specific signals to weigh:

• Eli Lilly litigation. In April 2025, Eli Lilly sued Henry Meds (among other telehealth companies) over its marketing of compounded tirzepatide. In September 2025, a federal judge allowed Lilly's claim that Henry falsely advertises its compounded GLP-1s as "personalized" or "patient-specific" to proceed, while dismissing (for now) the broader claim that Henry marketed the products as "safe and effective." This is unresolved litigation, not a finding of wrongdoing, but it directly concerns the legal theory the business depends on.
• Mixed trust indicators. Henry holds a high Trustpilot score across a large volume of reviews, yet Trustpilot has at times flagged its review activity for suspected inauthentic reviews, and Henry has carried a poor Better Business Bureau rating tied to unresolved complaints. Treat aggregate star ratings with caution and read the substance of recent complaints.

None of this means Henry is a scam — many patients report smooth experiences and good outcomes. It means the product category sits on legally shifting ground, supply could be disrupted by enforcement or litigation, and you are taking a non-FDA-reviewed medication. Those are material facts, not footnotes.

What are the side effects and safety concerns?

The side-effect profile of the molecules is well characterized from the branded trials. The most common effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain, usually worst during dose escalation and easing over time (FDA labeling for Wegovy and Zepbound). Slow titration and the included anti-nausea medication help.

Serious but rarer risks carry FDA labeling attention:

• Boxed warning for thyroid C-cell tumors based on rodent studies; these drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (FDA).
• Pancreatitis, gallbladder disease, kidney injury (often from dehydration due to vomiting), and rare cases of bowel obstruction/ileus from slowed gut motility.
• Hypoglycemia risk rises when combined with insulin or sulfonylureas.
• Not for use in pregnancy.

A risk specific to compounding is dosing error. The FDA has received reports of patients overdosing on compounded semaglutide because of confusion measuring doses from multi-dose vials and unfamiliar concentrations (FDA). Pre-filled, clearly labeled supplies and provider-guided titration reduce this risk, but it is real and is a reason the live-video visit option matters.

Who is Henry Meds best for — and who should skip it?

A reasonable fit if you: are a cash-pay patient who cannot access or afford brand-name GLP-1s through insurance; meet clinical criteria (BMI 30+, or 27+ with a comorbidity); value an all-inclusive monthly fee with no surprise add-ons; want a real video visit option rather than questionnaire-only prescribing; and understand and accept that you are taking a non-FDA-reviewed compounded medication.

You should skip Henry (or choose a brand-name route) if you: can get FDA-approved Wegovy/Zepbound covered by insurance — that is the gold standard and worth pursuing first; have a contraindication (personal/family history of medullary thyroid cancer or MEN 2, prior pancreatitis, pregnancy); want the regulatory certainty of an FDA-approved finished product; or are uncomfortable with a category facing active litigation and possible supply disruption. The oral compounded options in particular warrant skepticism, since their efficacy is the least supported by evidence.

How does Henry compare to alternatives?

• Brand-name GLP-1s (Wegovy, Zepbound, Ozempic, Mounjaro): FDA-approved, evidence-backed finished products — the only options with proven manufacturing quality. They have traditionally been pricier without coverage, but manufacturer self-pay programs (LillyDirect for Zepbound, NovoCare for Wegovy) have lowered cash prices into the low-hundreds-per-month range for some doses as of late 2025. If insurance or one of these cash programs makes them affordable, they win.
• Other compounded-GLP-1 telehealth (Hims, Ro, Eden, Found, etc.): Henry's differentiators are its all-inclusive bundle, generous supplies, included anti-nausea med, and a live-video visit option in many states. Its weaknesses are dose-dependent price creep and pricing opacity. Some competitors offer flat, dose-independent pricing, which can be cheaper at maintenance doses — worth comparing on the *maintenance* price, not the teaser.
• In-person obesity-medicine clinic: Strongest clinical oversight and best for complex cases or insurance navigation, but less convenient and often more costly up front.

The bottom line

Henry Meds is one of the more polished operators in the compounded-GLP-1 telehealth space: a genuinely all-inclusive monthly fee, careful cold-chain shipping, proactive anti-nausea support, and a real video-visit option that beats questionnaire-only prescribing. For a cash-pay patient who can't access branded GLP-1s, it's a credible, lower-cost route to the same molecules — with the GLP-1 evidence base (STEP 1, SURMOUNT-1, SURMOUNT-5) being among the strongest in modern obesity medicine.

But the core caveats are not optional reading. You would be taking a compounded drug the FDA has not reviewed, in a category whose legal foundation collapsed when the shortages ended in 2025, amid active Eli Lilly litigation that targets the very "personalized" framing Henry uses. Price creep with dose escalation and pre-intake pricing opacity make budgeting harder than the headline numbers suggest, and the oral formulations are the weakest-supported part of the lineup. The single most valuable step before signing up is to check whether your insurance will cover FDA-approved Wegovy or Zepbound — and to compare a current LillyDirect or NovoCare cash-pay quote, since manufacturer self-pay prices fell into the low hundreds per month for some doses in late 2025. If a branded route is affordable, that is the better path. If it isn't, Henry is a defensible choice among compounders, provided you go in with the maintenance-dose price, the regulatory risk, and the contraindications fully in view.